Raymond James analyst Gary Nachman initiated coverage of Ionis Pharmaceuticals with a Strong Buy rating and $63 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Ionis reports Phase 3 eplontersen study results published in JAMA
- Ionis Pharmaceuticals to hold a R&D Day
- Biotech Alert: Searches spiking for these stocks today
- Ionis and Roche announce agreement for two RNA investigation programs
- Bernstein keeps Underperform on Ionis, says Arrowhead’s ARO-APOC3 looks better
